Envisioning the future of early anticancer drug development
- PMID: 20535131
- DOI: 10.1038/nrc2870
Envisioning the future of early anticancer drug development
Abstract
The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.
Similar articles
-
Drug development and clinical trials--the path to an approved cancer drug.Nat Rev Clin Oncol. 2012 Feb 28;9(4):215-22. doi: 10.1038/nrclinonc.2012.22. Nat Rev Clin Oncol. 2012. PMID: 22371130 Review.
-
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Drug Discov Today. 2010 Feb;15(3-4):88-97. doi: 10.1016/j.drudis.2009.11.006. Epub 2009 Dec 2. Drug Discov Today. 2010. PMID: 19961955 Review.
-
Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.Cancer Discov. 2011 Aug;1(3):207-12. doi: 10.1158/2159-8290.CD-11-0161. Cancer Discov. 2011. PMID: 22586572
-
Compressing drug development timelines in oncology using phase '0' trials.Nat Rev Cancer. 2007 Feb;7(2):131-9. doi: 10.1038/nrc2066. Nat Rev Cancer. 2007. PMID: 17251919 Review.
-
Assessing tumor-related signs and symptoms to support cancer drug approval.J Biopharm Stat. 2004 Feb;14(1):5-21. doi: 10.1081/BIP-120028503. J Biopharm Stat. 2004. PMID: 15027497 Review.
Cited by
-
Beta-blocker use and breast cancer outcomes: a meta-analysis.Breast Cancer Res Treat. 2024 Aug;206(3):443-463. doi: 10.1007/s10549-024-07263-4. Epub 2024 Jun 5. Breast Cancer Res Treat. 2024. PMID: 38837086 Free PMC article. Review.
-
Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma.Cell Rep Med. 2024 Feb 20;5(2):101414. doi: 10.1016/j.xcrm.2024.101414. Epub 2024 Feb 7. Cell Rep Med. 2024. PMID: 38330942 Free PMC article. Clinical Trial.
-
Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors.Heliyon. 2024 Jan 10;10(2):e24452. doi: 10.1016/j.heliyon.2024.e24452. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38293546 Free PMC article.
-
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.Cancer Discov. 2023 Oct 5;13(10):2131-2149. doi: 10.1158/2159-8290.CD-23-0280. Cancer Discov. 2023. PMID: 37712571 Free PMC article.
-
New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells.Cancer Cell Int. 2022 Nov 15;22(1):356. doi: 10.1186/s12935-022-02782-w. Cancer Cell Int. 2022. PMID: 36376934 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources